Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR22588-118] to IL-2 Receptor alpha - BSA and Azide free
- Suitable for: WB, IP
- Reacts with: Mouse
Product nameAnti-IL-2 Receptor alpha antibody [EPR22588-118] - BSA and Azide free
See all IL-2 Receptor alpha primary antibodies
DescriptionRabbit monoclonal [EPR22588-118] to IL-2 Receptor alpha - BSA and Azide free
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-Fr or IHC-P
Species reactivityReacts with: Mouse
Recombinant fragment within Mouse IL-2 Receptor alpha aa 1-250. The exact sequence is proprietary.
Database link: P01590
- WB: EL4 and WEIH-231 whole cell lysates. IP: WEIH-231 whole cell lysate.
Ab256168 is the carrier-free version of ab255732. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
ab256168 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze.
Storage bufferConstituent: PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab256168 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Detects a band of approximately 50 kDa (predicted molecular weight: 31 kDa).|
|IP||Use at an assay dependent concentration.|
FunctionReceptor for interleukin-2.
Involvement in diseaseGenetic variations in IL2RA are associated with susceptibility to diabetes mellitus insulin-dependent type 10 (IDDM10) [MIM:601942]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Sequence similaritiesContains 2 Sushi (CCP/SCR) domains.
- Information by UniProt
- Interleukin 2 receptor alpha chain antibody
- CD25 antibody
- CD25 antigen antibody
IL-2 Receptor alpha was immunoprecipitated from 0.35 mg of WEHI-231 (mouse lymphoblast B cell lymphoma cell line) whole cell lysate with ab255732 at 1/40 dilution. Western blot was performed from the immunoprecipitate using ab255732 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used as secondary antibody at 1/5000 dilution.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 15 seconds.
IL-2 Receptor alpha is a glycoprotein, the molecular weight observed is consistent with what has been described in the literature (PMID: 17475646).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab255732).
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab256168 has not yet been referenced specifically in any publications.